Altea Research Institute

Las Vegas, Nevada 89102

0 studies enrolling now · 32 studies all time

What they study most

Acute Schizophrenia, Attention-Deficit/Hyperactivity Disorder, Attention-Deficit/Hyperactivity Disorder (ADHD), Bipolar Disorder, Cocaine-Related Disorders, Depression, Depressive Disorder, Major, Early Alzheimer's Disease, Early Alzheimer´s Disease, Episodic Migraine, Generalized Anxiety Disorder, Major Depressive Disorder

Studies at this site

• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) — Completed
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) — Completed
• A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant — Completed
• An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5) — Completed
• A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder — Completed
• This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year — Stopped early
• This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months — Stopped early
• 54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide — Completed
• A Study of JZP150 in Adults With Posttraumatic Stress Disorder — Completed
• An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4) — Completed
• Randomized Trial of Adult Participants With Generalized Anxiety Disorder — Completed
• Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD — Completed
• A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia — Completed
• A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2) — Completed
• Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine — Completed
• Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD — Completed
• Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4) — Stopped early
• Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension — Completed
• Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia — Completed
• A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite® — Stopped early
• Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine — Completed
• Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD) — Completed
• Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD) — Stopped early
• Study of Rapastinel as Monotherapy in Patients With MDD — Stopped early
• A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder — Stopped early
• Lorcaserin in the Treatment of Cocaine Use Disorder — Completed
• An Observational Study of Environmental and SocioEconomic Factors in Opioid Recovery — Completed
• Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression — Completed
• Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention — Completed
• Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients — Completed
• Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia — Completed
• A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia — Completed